Valsartan
Cat. No.：YN321180
CAS No. ：137862-53-4
| 产品名称: | Valsartan |
| CAS No.: | 137862-53-4 |
| Chemical Name: | N-(1-oxopentyl)-N-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-L-valine |
| Synonyms: | 缬沙坦; CGP 48933 |
| 分子量: | 435.52 |
| 分子式: | C₂₄H₂₉N₅O₃ |
| SMILES: | CC(C)[C@@H](C(O)=O)N(C(CCCC)=O)CC1=CC=C(C2=CC=CC=C2C3=NNN=N3)C=C1 |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | Valsarta (CGP-48933) 是血管紧张素II受体拮抗剂，有潜力用于高血压和心力衰竭的研究。 |
| IC50和靶点: | |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Frampton, J.E.Telmisartan: A review of its use in cardiovascular disease preventionDrugs71(6),651-677(2011)
Burnier, M.Angiotensin II type 1 receptor blockersCirculation103(6),904-912(2001)
Munger, M.A.Use of angiotensin receptor blockers in cardiovascular protection: Current evidence and future directionsPT36(1),22-40(2011)
Suematsu, Y., Miura, S., Goto, M., et al.LCZ696, an angiotensin receptor-neprilysin inhibitor, improves cardiac function with the attenuation of fibrosis in heart failure with reduced ejection fraction in streptozotocin-induced diabetic miceEur. J. Heart Fail.18(4),386-393(2016)
Irons, B.K., Tsikouris, J.P., and Thomas, A.A.The use of angiostensin receptor blockers in the treatment of chronic hear failureJ. Cardiovasc. Pharmacol.44(6),718-724(2004)
Schiffrin, E.L.Beyond blood pressure: The endothelium and atherosclerosis progressionAm. J. Hypertens.15(10 Pt 2),115S-122S(2002)
